文献速递冠心病血脂与心血管预防

omega-3脂肪酸补充剂与心血管疾病风险的关联:10项试验77,917人的荟萃分析

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
PubMed 文献 · JAMA Cardiol · 2018-01-01

结果显示,随机接受omega-3脂肪酸补充(EPA剂量范围226-1800 mg/d)与冠心病死亡、非致命性心肌梗死、任何冠心病事件或主要血管事件均无显著关联,不支持现有指南对冠心病史患者使用此类补充剂的推荐。

要点

  • omega-3脂肪酸补充与冠心病死亡、非致命心梗及主要血管事件均无显著关联。
  • 亚组分析(包括既往冠心病、糖尿病、他汀使用等)中亦未见显著关联。
  • 结果不支持对冠心病史患者常规推荐omega-3脂肪酸补充剂。

核心结论

  • omega-3脂肪酸补充与致命性或非致命性冠心病及任何主要血管事件均无显著关联。
  • 该结果不支持现有指南对冠心病史患者使用omega-3脂肪酸补充剂的推荐。

研究设计与样本

  • 纳入试验要求至少500名参与者且治疗持续时间至少1年,并评估omega-3脂肪酸与血管事件风险的关联。
  • 汇总数据采用固定效应荟萃分析,主要疾病使用95%置信区间,所有亚组使用99%置信区间。

主要发现

  • 随机接受omega-3脂肪酸补充(EPA剂量范围226-1800 mg/d)与冠心病死亡无显著关联(RR 0.93;99% CI 0.83-1.03;P=.05)。
  • 与安慰剂相比,omega-3脂肪酸补充与非致命性心肌梗死无显著关联(RR 0.97;99% CI 0.87-1.08;P=.43)。
  • 与安慰剂相比,omega-3脂肪酸补充与任何冠心病事件无显著关联(RR 0.96;95% CI 0.90-1.01;P=.12)。
  • 与安慰剂相比,omega-3脂肪酸补充与主要血管事件无显著关联(RR 0.97;95% CI 0.93-1.01;P=.10),总体及各亚组(包括既往冠心病、糖尿病、血脂高于特定切点或他汀使用)均如此。

临床怎么用

  • 对于有冠心病史的患者,不应仅基于现有指南推荐而常规处方omega-3脂肪酸补充剂以预防心血管事件。
  • 临床决策应基于个体化评估,并参考最新证据更新对omega-3脂肪酸补充剂的认识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current guidelines advocate the use of marine-derived omega-3 fatty acids supplements for the prevention of coronary heart disease and major vascular events in people with prior coronary heart disease, but large trials of omega-3 fatty acids have produced conflicting results. OBJECTIVE: To conduct a meta-analysis of all large trials assessing the associations of omega-3 fatty acid supplements with the risk of fatal and nonfatal coronary heart disease and major vascular events in the full study population and prespecified subgroups. DATA SOURCES AND STUDY SELECTION: This meta-analysis included randomized trials that involved at least 500 participants and a treatment duration of at least 1 year and that assessed associations of omega-3 fatty acids with the risk of vascular events. DATA EXTRACTION AND SYNTHESIS: Aggregated study-level data were obtained from 10 large randomized clinical trials. Rate ratios for each trial were synthesized using observed minus expected statistics and variances. Summary rate ratios were estimated by a fixed-effects meta-analysis using 95% confidence intervals for major diseases and 99% confidence intervals for all subgroups. MAIN OUTCOMES AND MEASURES: The main outcomes included fatal coronary heart disease, nonfatal myocardial infarction, stroke, major vascular events, and all-cause mortality, as well as major vascular events in study population subgroups. RESULTS: Of the 77 917 high-risk individuals participating in the 10 trials, 47 803 (61.4%) were men, and the mean age at entry was 64.0 years; the trials lasted a mean of 4.4 years. The associations of treatment with outcomes were assessed on 6273 coronary heart disease events (2695 coronary heart disease deaths and 2276 nonfatal myocardial infarctions) and 12 001 major vascular events. Randomization to omega-3 fatty acid supplementation (eicosapentaenoic acid dose range, 226-1800 mg/d) had no significant associations with coronary heart disease death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .05), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43) or any coronary heart disease events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). Neither did randomization to omega-3 fatty acid supplementation have any significant associations with major vascular events (RR, 0.97; 95% CI, 0.93-1.01; P = .10), overall or in any subgroups, including subgroups composed of persons with prior coronary heart disease, diabetes, lipid levels greater than a given cutoff level, or statin use. CONCLUSIONS AND RELEVANCE: This meta-analysis demonstrated that omega-3 fatty acids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events. It provides no support for current recommendations for the use of such supplements in people with a history of coronary heart disease.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018. PMID: 29387889. doi:10.1001/jamacardio.2017.5205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。